8-K filing — NextCure, Inc. (NXTC)
Filed: 2026-09-25 AccNo: 0001104659-26-110971 Size: 303 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Nextcure Transforms Into Avere as Investors Back Oral Psoriasis Therapy
NextCure will merge with Avere in a $320 million exchange to advance oral IL-23 therapy AVR-001 and list the combined company as AVRX.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Avere Therapeutics Announces $500M Private Placement On Top Of Previously Announced $320M Concurrent Financing, Funding Operations Into 2029 Ahead Of NextCure Merger
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's after-market session. The company's market cap stands at $1.9 billion. As per the news, the Q2 earnings report came out
NextCure Q2 EPS $(2.80) Misses $(1.94) Estimate
NextCure (NASDAQ:NXTC) reported quarterly losses of $(2.80) per share which missed the analyst consensus estimate of $(1.94) by 45.08 percent. This is a 75.2 percent increase over losses of $(11.29) per share from the